Major expansion of facility for manufacturing drug substances
Last December, this company officially opened (photo) its£6-million project expansion project in Alnwick, U.K. The new facility provides a state-of-the-art drug-substance manufacturing capability that can deliver integrated support for drug-candidate selection through to early clinical development and beyond. The expansion delivers multipurpose capacity of up to 15 GMP reactor streams with reactor volumes ranging from 5 to 150 L, and tactical deployment of batch or continuous-flow chemistry technologies to optimize drug substance manufacturing processes. The facility has been designed adopting Industry 4.0 principles, with the inclusion of a predictive process control system (PharmaMV), improving the transfer from small-scale process research and development (PR&D) into manufacture of multi-kilogram quantities of drug substance for clinical use. — Stand 1260 — Quotient Sciences, Nottingham, U.K.